



Cite this: *Lab Chip*, 2023, 23, 3289

Continuous molecular monitoring of human dermal interstitial fluid with microneedle-enabled electrochemical aptamer sensors†

Mark Friedel,^a Benjamin Werbovetz,^a Amy Drexelius,^a Zach Watkins,^a Ahilya Bali,^a Kevin W. Plaxco^b and Jason Heikenfeld^a

The ability to continually collect diagnostic information from the body during daily activity has revolutionized the monitoring of health and disease. Much of this monitoring, however, has been of physical “vital signs”, with the monitoring of molecular markers having been limited to glucose, primarily due to the lack of other medically relevant molecules for which continuous measurements are possible in bodily fluids. Electrochemical aptamer sensors, however, have a recent history of successful *in vivo* demonstrations in rat animal models. Herein, we present the first report of real-time human molecular data collected using such sensors, successfully demonstrating their ability to measure the concentration of phenylalanine in dermal interstitial fluid after an oral bolus. To achieve this, we used a device that employs three hollow microneedles to couple the interstitial fluid to an *ex vivo*, phenylalanine-detecting sensor. The resulting architecture achieves good precision over the physiological concentration range and clinically relevant, 20 min lag times. By also demonstrating 90 days dry room-temperature shelf storage, the reported work also reaches another important milestone in moving such sensors to the clinic. While the devices demonstrated are not without remaining challenges, the results at minimum provide a simple method by which aptamer sensors can be quickly moved into human subjects for testing.

Received 11th March 2023,
Accepted 6th June 2023

DOI: 10.1039/d3lc00210a

rsc.li/loc

Introduction

Wearable devices supporting the continuous monitoring of glucose in dermal interstitial fluid have transformed the management of diabetes. This singular, but major, success in the high-frequency measurement of a molecular biomarker¹ has inspired broader pursuit of biosensors supporting similarly real-time, high-frequency measurements of markers indicative of numerous other diseases and health conditions that could benefit from continuous monitoring.

Dermal interstitial fluid (ISF) is a biofluid suitable for continuous molecular monitoring. ISF is the fluid surrounding cells in the body, with dermal ISF readily accessible in the skin (dermis and hypodermis) less than 1 mm below the surface. Dermal ISF is rich in biomolecules; it contains >90% of the proteins, RNAs, and metabolites found in blood, as well as molecules unique to the ISF.^{2–4} Despite

this wealth of information ISF is not commonly used in diagnostics. Instead, blood is the most utilized, well-characterized, and well understood biofluid; however, continuously accessing blood is rather invasive. In contrast, an array of methods exist for access of dermal ISF, although for many extraction is either slow (nL h^{-1}) or alters analyte concentrations when taken more rapidly at higher volumes.⁵ These small volumes of fluid can then be analysed by mass spectroscopy and immunoassays.^{4,6} For continuous glucose monitoring for Diabetics, there was little reason to further navigate ISF and the diagnostic challenges it presents. However, now that technology for continuous molecular monitoring is rapidly advancing, ISF is now receiving greater attention as a diagnostic fluid.⁵

Continuous measurements of ISF analytes without ISF extraction could redefine the approach to critical care and personalized medicine. Continuous molecular monitoring of ISF, for example, could enable earlier detection of diseases and more precise interventions tailored to an individual's unique physiology. Therapeutic-drug monitoring in ISF could improve the safety and efficacy of life-saving pharmaceuticals that suffer from narrow therapeutic ranges. One example is vancomycin with its narrow therapeutic window, high patient-to-patient variability in protein binding, and the potential for dangerous side effects.^{7–9} Indeed, in some cases

^a Novel Devices Laboratory, College of Engineering, University of Cincinnati, Cincinnati, Ohio 45221, USA. E-mail: friedemc@mail.uc.edu

^b Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106, USA

† Electronic supplementary information (ESI) available: 2D AutoCAD files for device parts & shadow mask are provided. Additional sensor data is also available. See DOI: <https://doi.org/10.1039/d3lc00210a>

measurements of ISF may prove to be more useful than blood-based measures as it is a better indicator of tissue concentrations, specifically when the target tissue is within the dermis.¹⁰ It should not be lost that ISF is not as well understood for diagnostics as blood;⁵ however, the ability to continuously access ISF a few hundred microns below the skin surface in clinics or for everyday wear elevates its potential value in continuous monitoring.

Despite ISF's potentially great diagnostic value, only limited examples have been reported in which, like continuous glucose monitors, such devices have been adapted to small needle-based sensors suitable for performing measurements beneath the skin. Microneedles are a rapidly emerging approach for minimally invasive dermal ISF access. For example continuous enzymatic sensors have been employed with microneedles to measure glucose and a few other small molecules, including lactate, ethanol, and phenoxymethylpenicillin, in humans.^{11–13} To expand what is possible in molecular monitoring in ISF, electrochemical aptamer sensors^{14–25} are arguably the best positioned technology, as the successful *in vivo* measurement of more than a dozen molecules has been achieved using such sensors in the rat jugular. These early, animal-based tests, however, employed fairly invasive sensors fabricated on gold wire and introduced using an intravenous catheter^{14,15}

that would translate poorly to human subjects. Efforts using less-invasive means have been limited to testing of microneedles coated with aptamers inserted into rats that achieved an hour of data collection before failure.¹⁶

While the above demonstrations represent a significant advance in *in vivo* molecular monitoring, all prior electrochemical aptamer sensor reports have been limited to rats, the overwhelming majority of which were anesthetized during study. It is unclear how well such devices function in ambulatory animal studies, and even more uncertain in human subjects as no human data has been reported thus far. The primary challenge associated with moving to human subjects is that the device requirements are much more stringent than for animals. For example, for human use, an ideal device should be minimally invasive and allow for safe and easy insertion, wear, and removal. In support of this, and to increase design freedom, here we have employed *ex vivo* sensors coupled to the dermis *via* FDA-approved, hollow microneedles (Fig. 1b) that, because they penetrate less than 700 μm , are generally painless and avoid bleeding. This design also only introduces one foreign material, silicon, directly to the dermis, lowering the risk for immune response or unwanted materials leeching into the body. Finally, the *ex vivo* placement of the sensors in this design also allows for additional “modules,” such as a protective membrane or




Fig. 1 Schematics, images, and illustrations of wearable aptamer sensors for continuous molecular monitoring of dermal ISF. a. Potential application spaces for continuous, wearable aptamer sensors ranging from clinical cardiac or therapeutic drug monitoring to metabolic and health related consumer products. b. Visualization of device components and an image of the on-body device. c. A mock-up of a mobile application supporting continuous, aptamer-based sensing devices. d. Comparison of the 3×1 microneedle array used in this device with a standard, 18-gauge needle of the type commonly used in blood donation. e. A schematic of our microneedle device on-body with f. a schematic of the sensor mechanism.

components supporting the preconcentration of the analyte,^{17,26} to control the sensing environment in ways that cannot be achieved with an indwelling sensor.

Herein we report the first on-body human dose-response achieved with electrochemical aptamer sensors. While the phenylalanine sensor was previously characterized in buffer and *via* surgical placement in rat blood¹⁴ it, like all other aptamer sensors, has not yet been translated into human testing. By demonstrating the first in-human data for any type of continuous, affinity-based biosensor, our work has surmounted a number of key milestones in the practical, continuous molecular monitoring of analytes beyond glucose. Beyond the first demonstration of EAB sensors in human subjects, the work presented demonstrates practical tools for the manufacturing and dry shelf storage of devices employing electrochemical aptamer-based sensors. For this device fabrication work and related *in vivo* testing, we further demonstrate generalizability to other analytes (cortisol, vancomycin). Furthermore, we demonstrate the utility of employing simple gel-pad skin adhesive counter and reference electrodes, which simplify device construction and testing.¹⁸ Finally, our design reduces the skin damage of previous (enzymatic sensor) *in vivo* microneedle demonstrations, which required 10s to 100 s of perforations,^{11,12} by employing only 3. This device demonstrates the feasibility of electrochemical aptamers for use as a continuous, wearable molecular monitoring platform that, with further development, could be capable of detecting many other molecules relevant to human health and disease.

Results & discussion

Device structure and function

Our device is a low profile, minimally invasive, wearable design in which the sensor remains *ex vivo* and only FDA approved microneedles (from Nanopass Tech. Ltd.) enter the body (Fig. 1). These hollow, fluid-filled microneedles create a coupling that allows the analyte to rapidly diffuse to the sensor. This coupling also acts as a failsafe for immediate detection of failed insertions; without the fluidic connection between the sensor and the dermis, the device does not pass measurable currents. The device is relatively simple to construct: a gold working electrode modified with the target-recognizing aptamer is sealed against the microneedles (Fig. 1b) and then surrounded by a gel Ag/AgCl counter electrode that covers the surrounding skin surface. The fabricated device is placed onto the arm and gentle pressure is applied by hand to ensure microneedle penetration (no specialized “inserter” is required). In this work, we attached the electrodes to a bench-top CH Instruments potentiostat, and then employed square-wave voltammetry to interrogate the sensor. The device relies on diffusion of analytes to the sealed sensor cavity and is not capable of collecting appreciable amounts of ISF for *in vitro* analysis. With the addition of a miniaturized potentiostats,¹⁸ this approach could readily be adapted to a fully self-contained, wearable

device supporting continuous, real-time molecular monitoring (Fig. 1a and c).

Simulation results

Simulations of the time required to reach 90% of the “dermal” (*i.e.*, applied) analyte concentration at the sensor surface suggest that, for low molecular weight (<3 kDa) analytes, the lag times associated with our *ex vivo* sensor placement would be on the order of tens of minutes (Fig. 3a and b). To perform these simulations, we construct a model dermis, microneedle lumen, and sensor space, and then set a homogenous concentration throughout the entire model (Fig. 3a). Next, we spike the simulated dermis with 5 mM of the target analyte and monitor the concentration seen




Fig. 2 Device fabrication. Shown is the fabrication process employed for both the disc (left) and custom thin-film (right) gold electrode devices.




Fig. 3 Simulations and *in vitro* device validation. a. Schematic of the device on-body compared to the representative geometry used in simulations. b. Simulated results for worst-case scenario measurements of multiple analytes in our sensing device. c. Comparison of *in vitro* device lag to simulated results on planar electrodes for phenylalanine, d. cortisol, and e. vancomycin. f. Titration of analyte to microneedle + aptamer sensor disc electrodes for phenylalanine in pbs (full titration data can be found elsewhere¹⁴) and g. vancomycin in a dilute serum as an ISF analogue.

at the furthest point from the microneedle lumen. Doing so, we found that, with glucose (180 Da) as the target, the sensor surface reaches 90% of its final concentration within 20 min, a time scale that compares well with the previously demonstrated 11 min lag time of a similar, on-body, microneedle-based continuous glucose monitor.¹¹ Using the amino acid phenylalanine (165 Da) as the target this lag time decreases to 17 min, and for the antibiotic vancomycin (1449 Da) lag times increase to 50 min. Unsurprisingly, our device performs more poorly for higher molecular weight analytes. For inflammatory marker IL-6 (21 kDa), for example, the concentration at the distal site reaches only 31% of the dermal analyte concentration even after 2 h.

Sensor fabrication and preservation

Before use, we must prime our devices to create the required fluidic connection between ISF and our sensors. Due to the hydrophobic nature of the needle lumen, we employ vacuum to perform this priming. Unfortunately, however, electrochemical aptamer sensors lose functionality after

exposure to vacuum (Fig. 4b). We speculate that this is due to physical desorption of the sensor surface chemistries, removing both aptamers and portions of the mercaptohexanol monolayer (alkythiol molecules are still volatile even when bonded to gold at room temperature). To circumvent this, we deposited 10% trehalose solution onto the sensing surface and dry the sensors under vacuum, an approach similar to those often used to preserve DNA.²⁷ Such treatment not only preserves the aptamer, but also impedes the desorption of the gold-thiol bonds at the sensor surface (Fig. 4c). Critically, phenylalanine-detecting sensors dried in trehalose solution under vacuum and later rehydrated respond to their target with the same affinity and gain as we observed before drying (Fig. 4d).

In addition to protecting sensors during priming, trehalose treatment also preserves sensors for dry, long-term, room temperature storage—an important consideration for clinical devices. To show this, we tested trehalose preservation using two sensors: one targeting phenylalanine¹⁴ and a second targeting cortisol.¹⁸ We deposited trehalose




Fig. 4 Comparison of device design and storage effects on sensor functionality. a. Relative signal strength of various sensor fabrication methods and assemblies compared to a bare disc electrode using a phenylalanine sensor measured at 10 and 120 Hz. b. Visualization of destructive vacuum effects on unprotected eab sensors *via* effect on the square-wave voltammogram. c. Comparison of square-wave voltammograms before and after vacuum with 10% w/w trehalose preservation for phenylalanine sensors and d. a titration of these same sensors. e. Titration of cortisol and f. phenylalanine sensors after 90 days of dry trehalose storage with shaded error ranges. g. Bulk signal loss after 0, 7, 30, and 90 days of storage for cortisol and h. phenylalanine sensors.

solution on these sensors, dried them under vacuum, and stored them in dry nitrogen at room temperature for up to 90 days. After such storage, both sensors maintained their ability to respond to their targets after rehydrating in solution to remove the trehalose preservation layer (Fig. 4e and f). Specifically, at a square-wave frequency of 10 Hz, stored phenylalanine sensors exhibit a signal gain (relative signal change at a given target concentration) within the error of that seen in pre-storage controls. At higher frequencies (120 Hz for phenylalanine and 300 Hz for cortisol) the gain even increased slightly. This may be due to loss of non-specifically adsorbed aptamer, which would reduce the background signal and thus increase gain. Consistent with this, we see mild reductions in peak current after storage (Fig. 4g and h). This minor signal loss is independent of the length of storage, furthering the argument it is not outright sensor degradation and suggests that dry storage under trehalose may be extendable to well beyond 90 days.

Device design effects on signal strength

In this work, we have fabricated sensors using both commercial gold disc electrodes and custom, e-beam deposited, thin-film gold electrodes, both of which have advantages and disadvantages. Disc electrode fabrication is shown in the left side of Fig. 2 while thin-film fabrication is shown at right. Disc electrodes can be conveniently purchased commercially. Thin-film electrodes, in contrast, require more specialized tools to create, but they enable the placement of the entire 3-electrode reference/counter/working system on a single, small chip. A further concern for thin-film electrodes is that, even when the geometric surface area of both electrode types is the same the peak currents associated with the thin-film electrodes are less than half those of the disc electrodes (Fig. 4a). We believe this arises due to differences in the surface microstructure of the two electrode types. Disc electrodes, being reusable, are mechanically polished as part of preparation, a process that increases their roughness and thus their microscopic surface area (Fig. S1†). Consistent with this, cyclic voltammetric measures of the gold oxide reduction peak indicate that the electrochemically active surface area of disc electrodes is $38 \pm 1\%$ larger than that of thin-film electrodes of the same macroscopic dimensions (Fig. S2†). We also note that thin-film sensors report lower signal gains and have higher variability when challenged with target compared to disc electrodes (Fig. S3†). Unfortunately, our attempts to increase the microscopic surface area of the thin-film electrodes *via*, for example, mechanical polishing and electrochemical roughening,¹⁹ lead to poor reproducibility and increased sensor degradation (data not shown).

The peak currents of both disc and thin-film electrodes become poorer when these electrodes are integrated into microneedle devices. Specifically, the peak currents of

sensors fabricated on disc electrodes decreased by 30% to 40% and those fabricated on thin-film electrodes by 66% to 78% when these were integrated into microneedle devices. This may arise because the placement of electrodes in our microneedle devices limits the cross section of the solution available to pass current and possibly introducing charging currents as well with the microneedles as a capacitor in parallel with solution resistance in the needle lumens. The stored charge in such a circuit cannot be accurately quantified, leading to lower peak current measurements.

Device validation *in vitro*

Both thin-film and disc electrode devices achieved lag times of less than 30 min when we tested them *in vitro* (Fig. 3c–e). Specifically, the lag times of our phenylalanine, cortisol, and vancomycin sensors (lag times as defined above) were 10, 29, and 28 min, respectively. This is more rapid than predicted by our simulations, presumably due to two factors: the compensatory worst-case scenario simulation design and the assembly processes. For example, due to compression of the adhesive used to assemble our devices, the height of the sensing cavity is likely less than the 90 μm we designed, and smaller volumes will equilibrate more rapidly. Critically,

given that clinical devices must work over a large range of target concentrations, we found similar diffusion lag times across all target concentrations (Fig. 3f and g). The diffusion of analytes out of our devices, however, is slower than the rate of diffusion into them (*i.e.*, the lag time for falling concentrations is greater than that of rising concentrations). For example, when the analyte concentration outside the device was lowered from 250 μM to 0 μM , our phenylalanine detecting device required ~ 64 min before it reported 90% of the final concentration change (Fig. 3f). Our vancomycin detecting device behaved similarly, requiring ~ 154 min to fall 90% when the applied concentration was lowered from 500 μM to 0 μM (Fig. 3g). We do not have empirical evidence suggesting a cause for this slow analyte elimination, but similar challenges have been seen in another diffusion-limited electrochemical aptamer device.¹⁷

On-body device testing

Our microneedle-based devices support high frequency molecular measurements on human subjects. To show this, we first fixed a phenylalanine-detecting device (Fig. 1b) onto a subject's arm and initiated data collection. This first test was completed on the same subject with two separate, thin-




Fig. 5 On-body device testing. a. On-body signal response of planar electrodes worn to assess sensor warmup (fouling) effects with inset graph of voltammograms showing square-wave response over 5 h. b. Data adapted from Koopman *et al.*²⁸ showing blood phenylalanine levels after an oral bolus for comparison with c. on-body sensor response to phenylalanine dosage. d. Schematic of testing workflow.

film-electrodes devices tested in parallel. After an initial set of measurements were collected, the subject was allowed to move and to complete light, everyday tasks while periodically returning to the potentiostat to perform further measurements over the course of 5 h. During this entire period, the sensor remained coupled to dermal ISF (Fig. 5a). While we performed these measurements, the peak current decreased. This decrease is expected as it is seen regularly during *in vitro* testing in serum, as foulants diffuse to the sensing surface and reduce electron transfer.²⁰ Given that thin-film devices used a gold pseudo-reference, rather than a true reference electrode, the effects of fouling on this reference are noticed as a shift of the peak position on square wave voltammograms (Fig. 5a). This expected fouling data is in itself important, as it confirms proper diffusive coupling between the device and the human dermis. As noted previously, the signal produced by thin-film electrodes is weaker than that of disk electrodes (Fig. 4), and, in our attempts at human testing, exhibited shorter operational lifetimes and were prone to additional failures, such as loss of electrical contacts with the potentiostat. Given this, we performed all further testing with disc electrodes.

Following the above studies, we next tested disk electrode devices over longer durations and with the administration of the target, phenylalanine, to the subject. The devices detected the increase in ISF phenylalanine levels associated with an oral challenge (25 mg kg⁻¹) within 20 min, which then plateaued (Fig. 5c). This is consistent with the known physiology of phenylalanine, as previous blood draw-based studies reported a rapid increase in plasma phenylalanine with heightened levels sustained thereafter²⁸ (Fig. 5b). We do, however, observe a mild drift in signal after phenylalanine uptake (>30 min post ingestion), presumably due to sensor degradation (Fig. 5c) (note: all three traces in Fig. 5c were collected using devices tested on the same subject on different days. The same subject was used to minimize intrasubject variation that could further confound our comparisons shown in Fig. 5c). Aptamer sensor degradation can be quite complex and is often due to numerous simultaneously occurring mechanisms.²⁰ This degradation could be potentially resolvable using our recently reported methods to improve sensor longevity to greater than one week.²⁰

While overcoming device failures we also made significant compromises to achieve high frequency, on-body dose-response measurements. For example, when challenged free in solution, our phenylalanine aptamer sensor achieves greater signal gain and peak currents at higher square-wave frequencies whereas the opposite effect was measured *in vivo* (>60 Hz; Fig. S4†). At frequencies at or above 120 Hz the peak current of our microneedle device is either indistinguishable from noise or does not respond to challenge with phenylalanine. Because of this, which could be due to the capacitive-resistance charging effects present when including the epidermis into the electrical circuit, we collected our on-body data using a 10 Hz square-wave

frequency. By limiting our measurements to this single frequency, we are unable to determine absolute phenylalanine concentrations because we cannot employ calibration free measurement techniques.²¹ Ultimately, we could mitigate this effect by moving the counter electrode onto the backside of the microneedle substrate to remove the epidermis from the device circuit.

Unfortunately, achieving the limited datasets presented here was not a trivial task due, in part, to considerable device failure rates. The exact modality of failure is difficult to determine given that the requirements to maintain sterility during sensor fabrication make sensor inspection and *in vitro* testing difficult. Electrical connections may be lost if leads are damaged during device assembly or during device application. If devices were not fixed well to the body mechanical failure could decouple electrodes from the microneedle-holding adhesive. Lastly, fluidic contact was sometimes quickly lost in devices placed on body, which could be due to air being introduced to the needle lumen during insertion or draining of priming buffer into the dermis given that the dermis has a pressure that is lower than ambient pressure.

It is also of value to note the limitations of early clinical testing. Blood collections and the use of compounds such as the catabolic hormone cortisol or antibiotic vancomycin increase the invasiveness and risk of device testing. For early-stage work given the high-rates of device failures, blood draws and analysis were not performed to minimize burden on the test subject, and reserved for future work once more reliable and long-lasting devices are developed. Furthermore, extraction of ISF through a modified device or other means was not pursued as extraction of sufficient ISF volume would take hours (much slower than our data acquisition rate) and can change the composition of the ISF.⁵ This challenge further exemplifies the need for devices with on-board sensors to continuously monitor ISF. Now that feasibility of EAB-devices has been demonstrated herein, future work could include more robust devices with blood-paired measurements to better understand blood to ISF partitioning as well as testing against more useful—but potentially toxic, compounds such as vancomycin, or markers of disease which are only found in non-healthy subjects which raise device testing risk and burden.

Discussion

Herein, we demonstrate the first continuous measurements of affinity-based aptamer sensors in human subjects. We achieved this by coupling *ex vivo* sensors to ISF *via* minimally invasive, fluid-filled microneedles. In parallel, we report several advances in the manufacturing and storage of such devices. Although we faced multiple limitations in the design of this device, the results presented here demonstrate the feasibility of electrochemical aptamer-based sensors as a continuous sensing modality able to work directly on the human body. To move beyond feasibility studies, continued

research into the circuitry through the microneedles and dermis to improve the range of square-wave frequencies that can be employed for this and similar aptamer sensor devices is beneficial. Such learnings could unlock the ability to correct for sensor drift through kinetic differential measurement^{21,22} and to achieve quantitative *in vivo* measurements. Temperature effects were also not explored, which, while fairly stable inside the body, may be a bigger factor for an *ex vivo* sensor design deployed here because of effects of environmental temperature and the strong temperature dependence of some aptamers.

While the work presented here represents a milestone in our efforts to move beyond just continuous glucose monitoring, we believe the potential value of the specific approach used herein deserves additional comment. At this time, it is our opinion that the device presented here has strong utility as an academic research tool because: (1) the device presented leverages the use of simple disc electrodes, which are widely utilized for *in vitro* electrochemical sensor development; (2) leverages the use of commercial FDA-approved microneedles, thus easing development burden for other groups desiring to move to human testing; and (3) it places the sensors *ex vivo* such that any materials that are not biocompatible simply need be locally immobilized, easing development burden regarding safe insertion into and removal from human subjects. This said, however, it is difficult to speculate on the potential clinical utility of this microneedle device. As such, the technology described here may speed the ability in which others are able to pursue human testing of continuous biosensors.

Methods

Electrode fabrication

We pursued two different electrode formats in parallel, thin-film gold and gold disc electrodes, which we created using the following workflow (Fig. 2). Disc electrodes were constructed by cutting 2 mm diameter gold working electrodes (CH Instruments, Austin, TX) to ~4 mm in thickness. After cutting, a working electrode wire was connected to the newly exposed gold surface with conductive, AgCl epoxy 8331D (MG Chemicals, British Columbia, Canada) and insulated with epoxy to passivate the exposed wire. We fabricated our thin-film gold electrodes as follows. Borosilicate glass was prepared for deposition by cleaning in piranha (5 : 1 H₂SO₄ : H₂O₂) followed by e-beam deposition of a 10 nm titanium layer for adhesion followed by a 100 nm gold layer. We patterned thin-film electrodes *via* a wet etch process using AZ1518 positive photoresist with AZ400k developer (MicroChemicals, Ulm, Germany). Then we etched gold using *aqua regia* (3 : 1 HCl : HNO₃) followed by etching of titanium with a hydrofluoric acid (HF) solution (1 : 1 : 40 HF : H₂O₂ : H₂O). Residual photoresist was removed by rinsing with acetone. The CAD drawings for these custom electrodes are provided in the online supplemental material.

Sensor preparation

Thin-film and disc electrodes were functionalized into aptamer sensors using similar processes. Specifically, our disc electrodes required an additional cleaning step before functionalization with aptamer in which we mechanically polished them using micro cloths soaked in 0.3 μm alumina slurry (eDAQ, Colorado Springs, CO). Both electrode types were then electrochemically cleaned using cyclic voltammetry in base followed by acid similar to prior work.²³ After cleaning, we incubated the electrodes in 400 nM aptamer solution (sequences provided in Table 1) for 1 h at room temperature followed by overnight incubation in 5 mM 6-mercapto-1-hexanol (mercaptohexanol) at 4 °C. For *in vivo* testing the aptamer sensors were disinfected using CIDEX solution as reported previously.²⁴

Aptamer protection and storage testing

Disc electrodes were tested in 1× phosphate buffer saline (PBS), pH 7.4 with a short titration of target analytes using square-wave voltammetry (SWV) with a CH Instruments 620E potentiostat (CH Instruments, Austin, TX) at 120 Hz for cortisol sensors and 10 Hz and 300 Hz for phenylalanine sensors. Testing was completed using the following workflow: (1) we prepared the sensors as normal, (2) then we collected sensor data while titrating target (3) we washed the sensors in buffer solution (4) we dried the sensors under vacuum with 10% w/w trehalose in PBS solution (5) we placed the sensors into dry nitrogen storage (6) we rehydrated sensors and repeat the data collection of step 2. To store the sensors, we deposited trehalose solution onto the sensor surface then applied -25 inHg vacuum until the trehalose fully dried (~1 h). After storage, the sensors were rehydrated in PBS and retested under the same conditions as before storage.

Microneedle device assembly

Electrodes were assembled into microneedle devices using 3 × 1 arrays of 600-micron tall silicon microneedles with 30 μm radius lumens (Nanopass Technologies, Ness Ziona, Israel). These microneedles are FDA approved for human use with their existing indication being for injection of drugs into the skin. First, we laser cut adhesive spacers (Universal Laser Systems, Scottsdale, AZ) from double-sided, 90 μm thick microfluidic tape (9965, 3M, Saint Paul, MN) to attach the microneedles to the aptamer sensor substrate and to define the volume of the sensing cavity (Fig. 2). Prior to attaching the microneedles onto the sensor substrates, we coated the sensor electrodes with 10% w/w trehalose solution and dried them under vacuum. Then, we added autoclave sterilized microneedle substrate onto the adhesive spacer window. For thin-film electrodes, polyimide tape was used to electrically insulate any exposed gold. At this point, these devices may be shelf-stored in a dry, nitrogen environment for 90 days or more. Prior to human subjects testing the microneedles and sensing cavity were wetted with sterile PBS solution by placing the sensors under -25 inHg vacuum for 15 min and

Table 1 Aptamer sequences

Target	Sequence (5'–3')
Phenylalanine	SH-(CH ₂) ₆ -CGACC-GCGTT-TCCCA-AGAAA-GCAAG-TATTG-GTTGG-TCG-MB
Cortisol	MB-GGA-CGA-CGC-CAG-AAG-TTT-ACG-AGG-ATA-TGG-TAA-CAT-AGT-CGT-(CH ₂) ₆ -SH
Vancomycin	SH-(CH ₂) ₆ -CGAGG-GTACC-GCAAT-AGTAC-TTATT-GTTTCG-CCTAT-TGTGG-GTCGG-MB

MB stands for the redox reporter methylene blue and 'SH-(CH₂)₆' is the hexathiol attachment used to attach the aptamer sensor to gold electrodes.

then submerging them in PBS while still under vacuum. The vacuum was then released to fluidically fill the sensors and microneedles. All devices were tested immediately after filling. In future work, we speculate that a wicking hydrogel or other hydrophilic matrix could be placed in the microneedles to allow automatic filling without the need for this final vacuum filling step. CAD files with dimensions for the parts described below are included in the online supplemental files.

Simulating device lag time

Device lag time simulations were run in COMSOL to estimate the time required for an analyte in the dermis to reach and equilibrate in concentration inside the sensor cavity. As shown in Fig. 3a, a simple geometry was employed to track analyte partitioning from the dermis through the needle to the furthest point in the sensing cavity. Geometry was defined to match the thin-film sensors as follows: a 600 µm needle lumen with a 30 µm radius, a 90 µm tall sensor cavity with a 60 µm length to the furthest point, and a vastly larger dermis at 5 × 5 mm. Stabilized convection–diffusion kinetics were applied to a 2D axisymmetric model. Parametric sweeps were used to test various diffusivities of analytes: $7.8 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ for phenylalanine,²⁹ $6.7 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ for glucose,³⁰ $2.8 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ for vancomycin,³¹ and $2.7 \times 10^{-11} \text{ m}^2 \text{ s}^{-1}$ for Interleukin-6 (IL-6).³² We note that these simulations do not consider the population of aptamers on the sensor surface which for very low (picomolar) concentrations of analytes can increase lag time. Given the small volumes in the microneedle device, the amount of analyte bound to the aptamers (which are at $\sim 10^{11}$ – 10^{13} aptamers per cm^2)²⁵ can substantially reduce the free target concentration.

Device testing

We report both *in vitro* and *in vivo* results completed with the following considerations. We tested sensors *in vitro* using either PBS or raw bovine serum, the latter containing unknown concentrations of endogenous cortisol and phenylalanine. A CH Instruments potentiostat was used to collect square-wave voltammetry data periodically while analyte was added or the solution outside of the sensor was replaced to increase or lower target concentration (Fig. 3c–g). Human subjects testing was completed under protocols approved by the University of Cincinnati's Institutional Review Board. Phenylalanine sensing devices were built,

inserted into the dermis, and secured into place with medical tape (1776, 3M, Saint Paul, MN). Sensor longevity tests were performed for up to 6 h to track sensor fouling and stability while participants completed light daily tasks, returning for sensor measurements periodically. In dose–response tests, sensors were placed on body, and allowed to foul and equilibrate with endogenous phenylalanine for 2 h before continuous measurement began. After a short data collection period, participants received a 25 mg kg^{-1} phenylalanine dosed orally (Fig. 5d). On-body square-wave parameters tested were as follows: 35 mV amplitude pulse, step frequencies ranging from 10–60 Hz, and a 2 mV step potential.

Author contributions

Mark Friedel: conceptualization, formal analysis, investigation, methodology, supervision, validation, visualization, writing – original draft, writing – review & editing. Benjamin Werbovetz: investigation, validation, formal analysis. Amy Drexelius: investigation, validation. Zach Watkins: investigation. Ahilya Bali: investigation. Kevin W. Plaxco: funding acquisition, writing – review & editing. Jason Heikenfeld: conceptualization, funding acquisition, methodology, supervision, writing – review & editing.

Conflicts of interest

Author Heikenfeld is a co-founder of Kilele Health Inc. which is pursuing the commercialization of continuous wearable monitoring of analytes in ISF.

Acknowledgements

The authors at the University of Cincinnati acknowledge support from the U.S. Office of Naval Research Award #N00014-20-1-2764), from a National Science Foundation ECCS Award #2025720, from the National Science Foundation CBET Award #2125056, and from U.S. Air Force Office of Scientific Research USAF Contract No. FA9550-20-1-0117.

Notes and references

- 1 J. Heikenfeld, A. Jajack, B. Feldman, S. W. Granger, S. Gaitonde, G. Begtrup and B. A. Katchman, Accessing analytes in biofluids for peripheral biochemical monitoring, *Nat. Biotechnol.*, 2019, **37**, 407–419.

- 2 B. Q. Tran, P. R. Miller, R. M. Taylor, G. Boyd, P. M. Mach, C. N. Rosenzweig, J. T. Baca, R. Polsky and T. Glaros, Proteomic Characterization of Dermal Interstitial Fluid Extracted Using a Novel Microneedle-Assisted Technique, *J. Proteome Res.*, 2018, **17**, 479–485.
- 3 R. M. Taylor, P. R. Miller, P. Ebrahimi, R. Polsky and J. T. Baca, Minimally-invasive, microneedle-array extraction of interstitial fluid for comprehensive biomedical applications: transcriptomics, proteomics, metabolomics, exosome research, and biomarker identification, *Lab. Anim.*, 2018, **52**, 526–530.
- 4 P. R. Miller, R. M. Taylor, B. Q. Tran, G. Boyd, T. Glaros, V. H. Chavez, R. Krishnakumar, A. Sinha, K. Poorey, K. P. Williams, S. S. Branda, J. T. Baca and R. Polsky, Extraction and biomolecular analysis of dermal interstitial fluid collected with hollow microneedles, *Commun. Biol.*, 2018, **1**, 1–11.
- 5 M. Friedel, I. A. P. Thompson, G. Kasting, R. Polsky, D. Cunningham, H. T. Soh and J. Heikenfeld, Opportunities and challenges in the diagnostic utility of dermal interstitial fluid, *Nat. Biomed. Eng.*, 2023, 1–15.
- 6 P. P. Samant, M. M. Niedzwiecki, N. Raviele, V. Tran, J. Mena-Lapaix, D. I. Walker, E. I. Felner, D. P. Jones, G. W. Miller and M. R. Prausnitz, Sampling interstitial fluid from human skin using a microneedle patch, *Sci. Transl. Med.*, 2020, **12**, 571.
- 7 M. Rybak, B. Lomaestro, J. C. Rotschafer, R. Moellering Jr., W. Craig, M. Billeter, J. R. Dalovisio and D. P. Levine, Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, *Am. J. Health-Syst. Pharm.*, 2009, **66**, 82–98.
- 8 S. I. Blot, F. Pea and J. Lipman, The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents, *Adv. Drug Delivery Rev.*, 2014, **77**, 3–11.
- 9 J. M. Butterfield, N. Patel, M. P. Pai, T. G. Rosano, G. L. Drusano and T. P. Lodise, Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding, *Antimicrob. Agents Chemother.*, 2011, **55**, 4277–4282.
- 10 T. K. L. Kiang, U. O. Häfeli and M. H. H. Ensom, A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring, *Clin. Pharmacokinet.*, 2014, **53**, 695–730.
- 11 A. Jina, M. J. Tierney, J. A. Tamada, S. McGill, S. Desai, B. Chua, A. Chang and M. Christiansen, Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor, *J. Diabetes Sci. Technol.*, 2014, **8**, 483–487.
- 12 F. Tehrani, H. Teymourian, B. Wuerstle, J. Kavner, R. Patel, A. Furmidge, R. Aghavali, H. Hosseini-Toudeshki, C. Brown, F. Zhang, K. Mahato, Z. Li, A. Barfidokht, L. Yin, P. Warren, N. Huang, Z. Patel, P. P. Mercier and J. Wang, An integrated wearable microneedle array for the continuous monitoring of multiple biomarkers in interstitial fluid, *Nat. Biomed. Eng.*, 2022, 1–11.
- 13 T. M. Rawson, S. A. N. Gowers, D. M. E. Freeman, R. C. Wilson, S. Sharma, M. Gilchrist, A. MacGowan, A. Lovering, M. Bayliss, M. Kyriakides, P. Georgiou, A. E. G. Cass, D. O'Hare and A. H. Holmes, Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers, *Lancet Digital Health*, 2019, **1**, e335–e343.
- 14 A. Idili, J. Gerson, T. Kippin and K. W. Plaxco, Seconds-Resolved, In Situ Measurements of Plasma Phenylalanine Disposition Kinetics in Living Rats, *Anal. Chem.*, 2021, **93**(8), 4023–4032.
- 15 J.-W. Seo, K. Fu, S. Correa, M. Eisenstein, E. A. Appel and H. T. Soh, Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals, *Sci. Adv.*, 2021, **8**(1), DOI: [10.1126/sciadv.abk2901](https://doi.org/10.1126/sciadv.abk2901).
- 16 Y. Wu, F. Tehrani, H. Teymourian, J. Mack, A. Shaver, M. Reynoso, J. Kavner, N. Huang, A. Furmidge, A. Duvvuri, Y. Nie, L. M. Laffel, F. J. Doyle, M.-E. Patti, E. Dassau, J. Wang and N. Arroyo-Currás, Microneedle Aptamer-Based Sensors for Continuous, Real-Time Therapeutic Drug Monitoring, *Anal. Chem.*, 2022, **94**(23), 8335–8345.
- 17 Y. Yuan, M. DeBrosse, M. Brothers, S. Kim, A. Sereda, N. V. Ivanov, S. Hussain and J. Heikenfeld, Oil-Membrane Protection of Electrochemical Sensors for Fouling- and pH-Insensitive Detection of Lipophilic Analytes, *ACS Appl. Mater. Interfaces*, 2021, **13**, 53553–53563.
- 18 A. McHenry, M. Friedel and J. Heikenfeld, Voltammetry Peak Tracking for Longer-Lasting and Reference-Electrode-Free Electrochemical Biosensors, *Biosensors*, 2022, **12**, 782.
- 19 N. Arroyo-Currás, K. Scida, K. L. Ploense, T. E. Kippin and K. W. Plaxco, High Surface Area Electrodes Generated via Electrochemical Roughening Improve the Signaling of Electrochemical Aptamer-Based Biosensors, *Anal. Chem.*, 2017, **89**, 12185–12191.
- 20 Z. Watkins, A. Karajic, T. Young, R. White and J. Heikenfeld, Week-Long Operation of Electrochemical Aptamer Sensors: New Insights into Self-Assembled Monolayer Degradation Mechanisms and Solutions for Stability in Serum at Body Temperature, *ACS Sens.*, 2023, **8**(3), 1119–1131.
- 21 H. Li, P. Dauphin-Ducharme, G. Ortega and K. W. Plaxco, Calibration-Free Electrochemical Biosensors Supporting Accurate Molecular Measurements Directly in Undiluted Whole Blood, *J. Am. Chem. Soc.*, 2017, **139**, 11207–11213.
- 22 A. Idili, C. Parolo, G. Ortega and K. W. Plaxco, Calibration-Free Measurement of Phenylalanine Levels in the Blood Using an Electrochemical Aptamer-Based Sensor Suitable for Point-of-Care Applications, *ACS Sens.*, 2019, **4**, 3227–3233.
- 23 Y. Xiao, R. Y. Lai and K. W. Plaxco, Preparation of electrode-immobilized, redox-modified oligonucleotides for electrochemical DNA and aptamer-based sensing, *Nat. Protoc.*, 2007, **2**, 2875–2880.

- 24 J. Chung, L. Sepunaru and K. W. Plaxco, On the Disinfection of Electrochemical Aptamer-Based Sensors, *ECS Sens. Plus*, 2022, **1**, 011604.
- 25 R. J. White, N. Phares, A. A. Lubin, Y. Xiao and K. W. Plaxco, Optimization of electrochemical aptamer-based sensors via optimization of probe packing density and surface chemistry, *Langmuir*, 2008, **24**, 10513–10518.
- 26 A. Jajack, I. Stamper, E. Gomez, M. Brothers, G. Begtrup and J. Heikenfeld, Continuous, quantifiable, and simple osmotic preconcentration and sensing within microfluidic devices, *PLoS One*, 2019, **14**, e0210286.
- 27 N. V. Ivanova and M. L. Kuzmina, Protocols for dry DNA storage and shipment at room temperature, *Mol. Ecol. Resour.*, 2013, **13**, 890–898.
- 28 R. Koopman, N. Crombach, A. P. Gijzen, S. Walrand, J. Fauquant, A. K. Kies, S. Lemosquet, W. H. Saris, Y. Boirie and L. J. van Loon, Ingestion of a protein hydrolysate is accompanied by an accelerated in vivo digestion and absorption rate when compared with its intact protein, *Am. J. Clin. Nutr.*, 2009, **90**, 106–115.
- 29 T. Umecky, K. Ehara, S. Omori, T. Kuga, K. Yui and T. Funazukuri, Binary Diffusion Coefficients of Aqueous Phenylalanine, Tyrosine Isomers, and Aminobutyric Acids at Infinitesimal Concentration and Temperatures from (293.2 to 333.2) K, *J. Chem. Eng. Data*, 2013, **58**, 1909–1917.
- 30 M. Kreft, M. Lukšič, T. M. Zorec, M. Prebil and R. Zorec, Diffusion of D-glucose measured in the cytosol of a single astrocyte, *Cell. Mol. Life Sci.*, 2013, **70**, 1483–1492.
- 31 Q. Zhu, X. Gao, M. D. Brown, F. Eismont and W. Gu, Transport of Vancomycin and Cefepime Into Human Intervertebral Discs: Quantitative Analyses, *Spine*, 2019, **44**, E992.
- 32 G. J. Goodhill, Diffusion in Axon Guidance, *Eur. J. Neurosci.*, 1997, **9**, 1414–1421.